Could a simple scan replace biopsies for cancer immunotherapy?
NCT ID NCT07442292
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue biopsy. The trial plans to enroll 40 participants and has not yet started recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 68Ga-cPP-BCH (a radioactive peptide for PET imaging)
- What this could lead to
- If successful, this could provide a non-invasive way to predict which patients will respond to immunotherapy, avoiding unnecessary treatments.
- What could go wrong
- This is an early, small study (40 participants) that has not yet started recruiting. The imaging method may not accurately reflect PD-L1 levels or predict treatment response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer light up hidden cancers?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?